Moderna, COVID-19
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last month, the U.S. Food and Drug Administration also gave approval for the vaccine, as well as updated shots from Pfizer ( PFE) and BioNTech ( BNTX ).
COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in the fall of 2024." The organization recommends a six-month interval between COVID vaccines, "with a minimum of three months from the last dose."
Moderna's updated COVID-19 vaccine approved in Canada
Health Canada has authorized Moderna's updated COVID-19 vaccine to roll out in fall immunization campaigns. The new Spikevax formula targets the KP.2 subvariant, one of the latest offshoots of the Omicron variant of the virus that causes COVID-19.
Fight off the virus this fall with a 2024-2025 COVID-19 vaccine
It’s been over four years since the beginning of the COVID-19 pandemic. And since then, the virus has changed substantially.
Health Canada approves Moderna’s COVID-19 vaccine targeting latest variant
The KP.3 variant of SARS-CoV-2 is dominating in Canada right now, accounting for the majority of the COVID-19 cases in the country.
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians
Health Canada approves Novavax's updated COVID-19 vaccine for fall
Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up. The product, called Nuvaxovid, is a protein-based vaccine. Health Canada said the vaccine was updated to target the JN.
Moderna Shares Rise on Canada Government Approval of Updated Covid-19 Vaccine
Shares of Moderna rose after the company said that the government of Canada authorized its updated Covid-19 vaccine, joining the U.S. in the approval. The stock was up 4.5% at $72.28 in Tuesday afternoon trading, becoming the best performing stock of the S&P 500 and Nasdaq 100. The stock has, however, dropped 26% since the beginning of the year.
Moderna's updated COVID-19 vaccine for 2024-25 approved in Canada
Health Canada authorized Moderna's updated COVID-19 vaccine on Tuesday to roll out in fall and winter immunization campaigns.
First for Women on MSN2d
Why Do Some People Experience COVID-19 Vaccine Side Effects While Others Don't? Experts Weigh in
If you've received the COVID-19 vaccine, you may have experienced common side effects such as pain, fatigue, or fever, or ...
Moderna stock plunges nearly 20% as company reports poor COVID-19 vaccine sales and cuts to research plans
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...
WXPR13h
COVID-19 vaccine availability and surge in positive cases
Vaccines are recommended two months after your last COVID vaccination. If you recently had COVID, the CDC recommends to wait ...
BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...